[
  {
    "ts": "2025-11-09T22:00:00+00:00",
    "headline": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial",
    "summary": "RAHWAY, N.J., November 09, 2025--Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial",
    "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-220000796.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f94822fb-a61a-3b45-bd3d-ce417e703b2d",
      "content": {
        "id": "f94822fb-a61a-3b45-bd3d-ce417e703b2d",
        "contentType": "STORY",
        "title": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial",
        "description": "",
        "summary": "RAHWAY, N.J., November 09, 2025--Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial",
        "pubDate": "2025-11-09T22:00:00Z",
        "displayTime": "2025-11-09T22:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/89cb5730539b2082017373d0b9d115ca",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vE6bR1UMVBF4t0qKh_NXtg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/89cb5730539b2082017373d0b9d115ca.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_PM9f9Sd8THhZJWJcjZdg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/89cb5730539b2082017373d0b9d115ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-220000796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-enlicitide-decanoate-investigational-oral-220000796.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]